Gene Detail

Gene Symbol ROS1
Synonyms c-ros-1 | MCF3 | ROS
Gene Description ROS1, ROS proto-oncogene 1, receptor tyrosine kinase, is an orphan receptor tyrosine kinase that may activates multiple pathways involved in cell survival and transformation (PMID: 23719267). ROS1 fusion proteins frequently lead to constitutive activation of Ros1 signaling and have been identified in glioblastoma, non-small cell lung cancer, cholangiocarcinoma, ovarian cancer, gastric adenocarcinoma, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, glioma, and epithelioid hemangioendothelioma (PMID: 23719267, PMID: 30262706, PMID: 30171048, PMID: 3004937).
Entrez Id 6098
Chromosome 6
Map Location 6q22.1
Canonical Transcript NM_002944

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Variant Impact Protein Effect Variant Description Associated with drug Resistance
P1539S missense unknown ROS1 P1539S lies within the fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). P1539S has been identified in sequencing studies (PMID: 28153863), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
L1982F missense unknown ROS1 L1982F lies within the protein kinase domain of the Ros1 protein (UniProt.org). L1982F has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 25351743, PMID: 24218589), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
W1694* nonsense loss of function - predicted ROS1 W1694* results in a premature truncation of the Ros1 protein at amino acid 1694 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt), W1694* is predicted to lead to a loss of Ros1 protein function.
E341D missense unknown ROS1 E341D lies within the extracellular domain of the Ros1 protein (UniProt.org). E341D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E1990G missense unknown ROS1 E1990G lies within the protein kinase domain of the Ros1 protein (UniProt.org). E1990G has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 25351743), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
M2128V missense unknown ROS1 M2128V lies within the protein kinase domain of the Ros1 protein (UniProt.org). M2128V has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 25351743), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
R2096W missense unknown ROS1 R2096W lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2096W has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D2058G missense unknown ROS1 D2058G lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2058G has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
G1556R missense unknown ROS1 G1556R lies within the Fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). G1556R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
L567V missense unknown ROS1 L567V lies within the fibronectin type-III domain 3 of the Ros1 protein (UniProt.org). L567V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
Q617H missense unknown ROS1 Q617H lies within the fibronectin-type III domain 3 of the Ros1 protein (UniProt.org). Q617H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
V768L missense unknown ROS1 V768L lies within the extracellular domain of the Ros1 protein (UniProt.org). V768L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R2096L missense unknown ROS1 R2096L lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2096L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R2096Q missense unknown ROS1 R2096Q lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2096Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
V785M missense unknown ROS1 V785M lies within the extracellular domain of the Ros1 protein (UniProt.org). V785M has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
wild-type none no effect Wild-type ROS1 indicates that no mutation has been detected within the ROS1 gene.
S653F missense unknown ROS1 S653F lies within the fibronectin type-III domain 3 of the Ros1 protein (UniProt.org). S653F has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E1974K missense unknown ROS1 E1974K lies within the protein kinase domain of the Ros1 protein (UniProt.org). E1974K has been identified in the scientific literature (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2018).
K298* nonsense loss of function - predicted ROS1 E298* results in a premature truncation of the Ros1 protein at amino acid 298 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E298* is predicted to lead to a loss of Ros1 protein function.
D1192V missense unknown ROS1 D1192V lies within the extracellular domain of the Ros1 protein (UniProt.org). D1192V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
K2099N missense unknown ROS1 K2099N lies within the protein kinase domain of the Ros1 protein (UniProt.org). K2099N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D780Y missense unknown ROS1 D780Y lies within the extracellular domain of the Ros1 protein (UniProt.org). D780Y has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
act mut unknown gain of function ROS1 act mut indicates that this variant results in a gain of function in the Ros1 protein. However, the specific amino acid change has not been identified.
M1805V missense unknown ROS1 M1805V lies within the fibronectin type-III domain 9 of the Ros1 protein (UniProt.org). M1805V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018)
L2086I missense unknown ROS1 L2086I lies within the protein kinase domain of the Ros1 protein (UniProt.org). L2086I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
S1986Y missense unknown ROS1 S1986Y lies within the protein kinase domain of the Ros1 protein (UniProt.org). S1986Y has been demonstrated to occur as a secondary drug resistance mutation in the context of ROS1 fusions (PMID: 27401242), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
L1951R missense unknown ROS1 L1951R lies within the protein kinase domain of the Ros1 protein (UniProt.org). L1951R has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 25351743), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
K2228Q missense unknown ROS1 K2228Q lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). K2228Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
V2098I missense unknown ROS1 V2098I lies within the protein kinase domain of the Ros1 protein (UniProt.org). V2098I has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 24218589), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
G1915R missense unknown ROS1 G1915R lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). G1915R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
G2101A missense unknown ROS1 G2101A lies within the protein kinase domain of the Ros1 protein (UniProt.org). G2101A has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 25688157), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
M2134I missense unknown ROS1 M2134I lies within the protein kinase domain of the Ros1 protein (UniProt.org). M2134I has been identified in the scientific literature (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2018).
A1964T missense unknown ROS1 A1964T lies within the protein kinase domain of the Ros1 protein (UniProt.org). A1964T has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
A87T unknown unknown ROS1 A87T lies within the extracellular domain of the Ros1 protein (UniProt.org). A87T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
F2075C missense unknown ROS1 F2075C lies within the protein kinase domain of the Ros1 protein (UniProt.org). F2075C has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 28717217), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
R360I missense unknown ROS1 R360I lies within the extracellular domain of the Ros1 protein (UniProt.org). R360I has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E539* nonsense loss of function - predicted ROS1 E539* results in a premature truncation of the Ros1 protein at amino acid 539 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E539* is predicted to lead to a loss of Ros1 protein function.
E2308K missense unknown ROS1 E2308K lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E2308K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
rearrange unknown unknown ROS1 rearrange indicates an unspecified rearrangement of the ROS1 gene.
G666S missense unknown ROS1 G666S lies within the fibronectin type-III domain 3 of the Ros1 protein (UniProt.org). G666S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
V2089M missense unknown ROS1 V2089M lies within the protein kinase domain of the Ros1 protein (UniProt.org). V2089M has been identified in the scientific literature (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2018).
Y1960H missense unknown ROS1 Y1960H lies within the protein kinase domain of the Ros1 protein (UniProt.org). Y1960H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
Y718* nonsense loss of function - predicted ROS1 Y718* results in a premature truncation of the Ros1 protein at amino acid 718 of 2347 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), Y718* is predicted to lead to a loss of Ros1 protein function.
K1163N missense unknown ROS1 K1163N lies within the extracellular domain of the Ros1 protein (UniProt.org). K1163N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
K2003I missense unknown ROS1 K2003I lies within the protein kinase domain of the Ros1 protein (UniProt.org). K2003I has been not been biochemically characterized, but retains sensitivity to crizotinib and ceritinib in the context of CD74-ROS1 (PMID: 25351743 ).
K1552T missense unknown ROS1 K1552T lies within the Fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). K1552T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
S1986F missense unknown ROS1 S1986F lies within the protein kinase domain of the Ros1 protein (UniProt.org). S1986F has been demonstrated to occur as a secondary drug resistance mutation in the context of ROS1 fusions (PMID: 27401242), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
P1020fs frameshift loss of function - predicted ROS1 P1020fs results in a change in the amino acid sequence of the Ros1 protein beginning at aa 1020 of 2347, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), P1020fs is predicted to lead to a loss of Ros1 protein function.
A887V missense unknown ROS1 A887V lies within the extracellular domain of the Ros1 protein (UniProt.org). A887V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D2113N missense unknown ROS1 D2113N lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2113N has been demonstrated to enhance resistance to Ros1 tyrosine kinase inhibitors with a concurrent ROS1 G2032R in the context of Ros1 fusion in culture (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
E290* nonsense loss of function - predicted ROS1 E290* results in a premature truncation of the Ros1 protein at amino acid 290 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E290* is predicted to lead to a loss of Ros1 protein function.
E1902K missense unknown ROS1 E1902K lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E1902K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
P1440L missense unknown ROS1 P1440L lies within the extracellular domain of the Ros1 protein (UniProt.org). P1440L has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
T804N missense unknown ROS1 T804N lies within the extracellular domain of the Ros1 protein (UniProt.org). T804N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E2308* nonsense unknown ROS1 E2308* results in a premature truncation of the Ros1 protein at amino acid 2308 of 2347 (UniProt.org). E2308* has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
S2229C missense unknown ROS1 S2229C lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). S2229C has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
T2195S missense unknown ROS1 T2195S lies within the protein kinase domain of the Ros1 protein (UniProt.org). T2195S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
G365A missense unknown ROS1 G365A does not lie within any known functional domains of the Ros1 protein (UniProt.org). G365A has not been characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
Q1797H missense unknown ROS1 Q1797H lies within the fibronectin type-III domain 9 of the Ros1 protein (UniProt.org). Q1797H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
L2155S missense unknown ROS1 L2155S lies within the protein kinase domain of the Ros1 protein (UniProt.org). L2155S has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 25688157), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
Q1889P missense unknown ROS1 Q1889P lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). Q1889P has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
G514fs frameshift loss of function - predicted ROS1 G514fs results in a change in the amino acid sequence of the Ros1 protein beginning at aa 514 of 2347, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the majority of the extracellular domain and the entire transmembrane and cytoplasmic domains (UniProt.org), G514fs is predicted to lead to a loss of Ros1 protein function.
N790S missense unknown ROS1 N790S lies within the extracellular domain of the Ros1 protein (UniProt.org). N790S has been identified in the scientific literature (PMID: 27900369), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D2033N missense unknown ROS1 D2033N lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2033N has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 26673800), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
N1534K missense unknown ROS1 N1534K lies within the Fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). N1534K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E1244* nonsense loss of function - predicted ROS1 E1244* results in a premature truncation of the Ros1 protein at amino acid 1244 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E1244* is predicted to lead to a loss of Ros1 protein function.
amp none no effect ROS1 amplification indicates an increased number of copies of the ROS1 gene. However, the mechanism causing the increase is unspecified.
G2148V missense unknown ROS1 G2148V lies within the protein kinase domain of the Ros1 protein (UniProt.org). G2148V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R245I missense unknown ROS1 R245I lies within the fibronectin type-III domain 2 of the Ros1 protein (UniProt.org). R245I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R167Q missense unknown ROS1 R167Q lies within the fibronectin type-III domain 1 of the Ros1 protein (UniProt.org). R167Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D2113G missense unknown ROS1 D2113G lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2113G has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
L1947R missense unknown ROS1 L1947R lies within the protein kinase domain of the Ros1 protein (UniProt.org). L1947R has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 24218589), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
P151S missense unknown ROS1 P151S lies within the fibronectin type-III domain 1 of the Ros1 protein (UniProt.org). P151S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
N2240K missense unknown ROS1 N2240K lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). N2240K has not been identified in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
F383S missense unknown ROS1 F383S lies within the extracellular domain of the Ros1 protein (UniProt.org). F383S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
mutant unknown unknown ROS1 mutant indicates an unspecified mutation in the ROS1 gene.
G1971E missense unknown ROS1 G1971E lies within the protein kinase domain of the Ros1 protein (UniProt.org). G1971E has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 24218589), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
fusion fusion unknown ROS1 fusion indicates a fusion of the ROS1 gene, but the fusion partner is unknown.
A2081T missense unknown ROS1 A2081T lies within the protein kinase domain of the Ros1 protein (UniProt.org). A2081T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
S1577Y missense unknown ROS1 S1577Y lies within the fibronectin type-III domain 7 of the Ros1 protein (UniProt.org). S1577Y has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R77W missense unknown ROS1 R77W lies within the extracellular domain of the Ros1 protein (UniProt.org). R77W has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
V1979E missense unknown ROS1 V1979E lies within the protein kinase domain of the Ros1 protein (UniProt.org). V1979E has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
W1817* nonsense loss of function - predicted ROS1 W1817* results in a premature truncation of the Ros1 protein at amino acid 1817 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), W1817* is predicted to lead to a loss of Ros1 protein function.
E2265D missense unknown ROS1 E2265D lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E2265D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
P1440S missense unknown ROS1 P1440S lies within the extracellular domain of the Ros1 protein (UniProt.org). P1440S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
W21* nonsense loss of function - predicted ROS1 W21* results in a premature truncation of the Ros1 protein at amino acid 21 of 2347 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W21* is predicted to lead to a loss of Ros1 protein function.
R380I missense unknown ROS1 R380I lies within the extracellular domain of the Ros1 protein (UniProt.org). R380I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
F2004C missense unknown ROS1 F2004C lies within the protein kinase domain of the Ros1 protein (UniProt.org). F2004C has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
F923I missense unknown ROS1 F923I lies within the extracellular domain of the Ros1 protein (UniProt.org). F923I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R304I missense unknown ROS1 R304I lies within the extracellular domain of the Ros1 protein (UniProt.org). R304I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
V1729L missense unknown ROS1 V1729L lies within the fibronection type-III domain 8 of the Ros1 protein (UniProt.org). V1729L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E1737* nonsense loss of function - predicted ROS1 E1737* results in a premature truncation of the Ros1 protein at amino acid 1737of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E1737* is predicted to lead to a loss of Ros1 protein function.
E2131D missense unknown ROS1 E2131D lies within the protein kinase domain of the Ros1 protein (UniProt.org). E2131D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
positive unknown unknown ROS1 positive indicates the presence of the ROS1 gene, mRNA, and/or protein.
E1935G missense unknown ROS1 E1935G lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E1935G has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 24218589), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
P1020S missense unknown ROS1 P1020S lies within the Fibronectin type-III domain 4 of the Ros1 protein (UniProt.org). P1020S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
S32I missense unknown ROS1 S32I lies within the extracellular domain of the Ros1 protein (UniProt.org). S32I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R2078W missense unknown ROS1 R2078W lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2078W has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
K1887Q missense unknown ROS1 K1887Q lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). K1887Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R2083G missense unknown ROS1 R2083G lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2083G has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D1776H missense unknown ROS1 D1776H lies within the fibronectin type-III domain 9 of the Ros1 protein (UniProt.org). D1776H has been identified in sequencing studies (PMID: 25589003), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
F250L missense unknown ROS1 F250L lies within the Fibronectin type-III domain 2 of the Ros1 protein (UniProt.org). F250L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
L2026M missense unknown ROS1 L2026M lies within the protein kinase domain of the Ros1 protein (UniProt.org). L2060M has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 25351743), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
G2032R missense unknown ROS1 G2032R lies in the protein kinase domain of the Ros1 protein (UniProt.org). G2032R has been associated with resistance to Ros1 tyrosine kinase inhibitors in the context of ROS1 fusions in patients (PMID: 23724914, PMID: 25033171), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
G1027D missense unknown ROS1 G1027D lies within the fibronectin type-III domain 4 of the Ros1 protein (UniProt.org). G1027D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
G1954R missense unknown ROS1 G1954R lies within the protein kinase domain of the Ros1 protein (UniProt.org). G1954R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
P2130T missense unknown ROS1 P2130T lies within the protein kinase domain of the Ros1 protein (UniProt.org). P2130T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
F2075V missense unknown ROS1 F2075V lies within the protein kinase domain of the Ros1 protein (UniProt.org). F2075V has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
S1109L missense unknown ROS1 S1109L lies within the fibronectin type-III domain 5 of the Ros1 protein (UniProt.org). S1109L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E1840* nonsense loss of function - predicted ROS1 E1840* results in a premature truncation of the Ros1 protein at amino acid 1840 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E1840* is predicted to lead to a loss of Ros1 protein function.
R118Q missense unknown ROS1 R118Q lies within the fibronectin type III domain 1 of the Ros1 protein (UniProt.org). R118Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E919K missense unknown ROS1 E919K lies within the extracellular domain of the Ros1 protein (UniProt.org). E919K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
C72R missense unknown ROS1 C72R lies within the extracellular domain of the Ros1 protein (UniProt.org). C72R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
Y1700* nonsense loss of function - predicted ROS1 Y1700* results in a premature truncation of the Ros1 protein at amino acid 1700 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), Y1700* is predicted to lead to a loss of Ros1 protein function.
T145P missense unknown ROS1 T145P lies within the fibronectin type-III 1 domain of the Ros1 protein (UniProt.org). T145P has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
G2066C missense unknown ROS1 G2066C lies within the protein kinase domain of the Ros1 protein (UniProt.org). G2066C has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
P1020H missense unknown ROS1 P1020H lies within the Fibronectin type-III domain 4 of the Ros1 protein (UniProt.org). P1020H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D2213N missense unknown ROS1 D2213N lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2213N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
I537M missense unknown ROS1 I537M lies within the extracellular domain of the Ros1 protein (UniProt.org). I537M has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
S1581F missense unknown ROS1 S1581F lies within the fibronectin type-III repeat domain 7 of the Ros1 protein (UniProt.org). S1581F has been identified in the scientific literature (PMID: 27900369), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
E2020K missense unknown ROS1 E2020K lies within the protein kinase domain of the Ros1 protein (UniProt.org). F2020K has been demonstrated to enhance resistance to Ros1 tyrosine kinase inhibitors with a concurrent ROS1 G2032R in the context of Ros1 fusion in culture (PMID: 26372962), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
N1800T missense unknown ROS1 N1800T lies within the Fibronectin type-III domain 9 of the Ros1 protein (UniProt.org). N1800T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
D2247Y missense unknown ROS1 D2247Y lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). D2247Y has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
R2205I missense unknown ROS1 R2205I lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2205I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
C2060G missense unknown ROS1 C2060G lies within the protein kinase domain of the Ros1 protein (UniProt.org). C2060G has been demonstrated to confer resistance to Ros1 tyrosine kinase inhibitors in the context of Ros1 fusion in culture (PMID: 24218589), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, May 2018). Y
Y382H missense unknown ROS1 Y382H lies within the extracellular domain of the Ros1 protein (UniProt.org). Y382H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2018).
Molecular Profile Protein Effect Treatment Approaches
ROS1 P1539S unknown
ROS1 L1982F unknown
ROS1 W1694* loss of function - predicted
ROS1 E341D unknown
ROS1 E1990G unknown
ROS1 M2128V unknown
ROS1 R2096W unknown
ROS1 D2058G unknown
ROS1 G1556R unknown
ROS1 L567V unknown
ROS1 Q617H unknown
ROS1 V768L unknown
ROS1 R2096L unknown
ROS1 R2096Q unknown
ROS1 V785M unknown
ROS1 wild-type no effect
ROS1 S653F unknown
ROS1 E1974K unknown
ROS1 K298* loss of function - predicted
ROS1 D1192V unknown
ROS1 K2099N unknown
ROS1 D780Y unknown
ROS1 act mut gain of function
ROS1 M1805V unknown
ROS1 L2086I unknown
ROS1 S1986Y unknown
ROS1 fusion ROS1 L2026M ROS1 L1951R
ROS1 L1951R unknown
ROS1 K2228Q unknown
ROS1 V2098I unknown
ROS1 G1915R unknown
ROS1 G2101A unknown
ROS1 M2134I unknown
ROS1 A1964T unknown
ROS1 A87T unknown
ROS1 F2075C unknown
ROS1 R360I unknown
ROS1 E539* loss of function - predicted
ROS1 E2308K unknown
ROS1 rearrange unknown ROS1 Inhibitor
ROS1 G666S unknown
ROS1 V2089M unknown
ROS1 Y1960H unknown
ROS1 Y718* loss of function - predicted
ROS1 K1163N unknown
ROS1 K2003I unknown
ROS1 K1552T unknown
ROS1 S1986F unknown
ROS1 P1020fs loss of function - predicted
ROS1 A887V unknown
ROS1 D2113N unknown
ROS1 E290* loss of function - predicted
ROS1 E1902K unknown
ROS1 P1440L unknown
ROS1 T804N unknown
ROS1 E2308* unknown
ROS1 S2229C unknown
ROS1 T2195S unknown
ROS1 G365A unknown
ROS1 Q1797H unknown
ROS1 L2155S unknown
ROS1 Q1889P unknown
ROS1 G514fs loss of function - predicted
ROS1 N790S unknown
ROS1 D2033N unknown
ROS1 N1534K unknown
ROS1 E1244* loss of function - predicted
ROS1 amp no effect
ROS1 G2148V unknown
ROS1 R245I unknown
ROS1 R167Q unknown
ROS1 D2113G unknown
ROS1 L1947R unknown
ROS1 P151S unknown
ROS1 N2240K unknown
ROS1 F383S unknown
ROS1 mutant unknown
ROS1 G1971E unknown
ROS1 fusion KDR amp KIT amp PDGFRA amp
KIT D816G ROS1 fusion
ROS1 fusion unknown ROS1 Inhibitor
ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp
ROS1 fusion ERBB2 amp FGFR3 amp RET amp
ROS1 A2081T unknown
ROS1 S1577Y unknown
ROS1 R77W unknown
ROS1 V1979E unknown
ROS1 W1817* loss of function - predicted
ROS1 E2265D unknown
ROS1 P1440S unknown
ROS1 W21* loss of function - predicted
ROS1 R380I unknown
ROS1 F2004C unknown
ROS1 F923I unknown
ROS1 R304I unknown
ROS1 V1729L unknown
ROS1 E1737* loss of function - predicted
ROS1 E2131D unknown
ALK neg ROS1 pos
ROS1 positive unknown
ROS1 E1935G unknown
ROS1 P1020S unknown
ROS1 S32I unknown
ROS1 R2078W unknown
ROS1 K1887Q unknown
ROS1 R2083G unknown
ROS1 D1776H unknown
ROS1 F250L unknown
ROS1 L2026M unknown
ROS1 G2032R unknown
ROS1 G1027D unknown
ROS1 G1954R unknown
ROS1 P2130T unknown
ROS1 F2075V unknown
ROS1 S1109L unknown
ROS1 E1840* loss of function - predicted
ROS1 R118Q unknown
ROS1 E919K unknown
ROS1 C72R unknown
ROS1 Y1700* loss of function - predicted
ROS1 T145P unknown
ROS1 G2066C unknown
ROS1 P1020H unknown
ROS1 D2213N unknown
ROS1 I537M unknown
ROS1 S1581F unknown
ROS1 E2020K unknown
ROS1 N1800T unknown
ROS1 D2247Y unknown
ROS1 R2205I unknown
ROS1 C2060G unknown
ROS1 Y382H unknown
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 fusion ROS1 L2026M ROS1 L1951R non-small cell lung carcinoma resistant Ceritinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient co-harboring a ROS1 fusion, ROS1 L2026M, and ROS1 L1951R demonstrated resistance to treatment with Zykadia (ceritinib) (PMID: 29636358). 29636358
ROS1 fusion ROS1 L2026M ROS1 L1951R non-small cell lung carcinoma resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion progressed after 17 months of treatment with Xalkori (crizotinib) and was found to have acquired two additional mutations, ROS1 L2026M and ROS1 L1951R (PMID: 29636358). 29636358
ROS1 rearrange non-small cell lung carcinoma sensitive Lorlatinib Phase I Actionable In a Phase I trial, Lorlatinib (PF-06463922) treatment resulted in an objective response in 50% (6/12) of patients with non-small cell lung carcinoma harboring a ROS1 rearrangement (PMID: 29074098; NCT03052608). 29074098
ROS1 rearrange Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in complete response in 13% (1/12) and objection response in 75% (6/8) of patients with advanced solid tumors harboring rearrangement in ROS1 gene (AACR Apr 2016, Abstract # CT007). detail...
ROS1 rearrange Advanced Solid Tumor sensitive Entrectinib Phase I Actionable In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in an objective response rate of 86% (12/14) in patients with ROS-1 rearranged advanced solid tumors that were treatment-naive, but no response (0/6) in patients received prior Xalkori (crizotinib) (PMID: 28183697). 28183697
ROS1 rearrange non-small cell lung carcinoma no benefit Osimertinib Guideline Actionable EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org). detail...
ROS1 rearrange non-small cell lung carcinoma no benefit Erlotinib Guideline Actionable EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org). detail...
ROS1 rearrange non-small cell lung carcinoma sensitive NPS-1034 Preclinical - Cell culture Actionable In a preclinical study, NPS-1034 inhibited ROS1 activity and proliferation of a non-small cell lung cancer cell line harboring a ROS1 rearrangement in culture (PMID: 24165158). 24165158
ROS1 rearrange non-small cell lung carcinoma no benefit Gefitinib Guideline Actionable EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org). detail...
ROS1 rearrange non-small cell lung carcinoma predicted - sensitive Cabozantinib Clinical Study Actionable In a clinical case study, a patient with ROS1-rearranged non-small cell lung cancer with acquired resistance to Xalkori (crizotinib) demonstrated partial response to treatment with Cometriq (cabozantinib) prior to progressing after approximately 10 weeks (PMID: 27370605). 27370605
ROS1 rearrange non-small cell lung carcinoma no benefit Afatinib Guideline Actionable EGFR tyrosine kinase inhibitors including Tarceva (erlotinib), Iressa (gefitinib), Gilotrif (afatinib), and Tagrisso (osimertinib) are not indicated for use as subsequent therapy in ROS1 rearranged non-small cell lung cancer patients who relapsed on Alecensa (alectinib), Xalkori (crizotinib), or Zykadia (ceritinib) (NCCN.org). detail...
ROS1 rearrange non-small cell lung carcinoma sensitive Ceritinib Guideline Actionable Zykadia (ceritinib) is included in guidelines as first-line therapy for ROS1 rearranged non-small cell lung cancer, but is not indicated after patients became resistant to Xalkori (crizotinib) (NCCN.org). detail...
ROS1 rearrange non-small cell lung carcinoma sensitive Ceritinib Phase II Actionable In a Phase II trial, treatment with Zykadia (ceritinib) resulted in an overall response rate of 62% (20/32, including 1 complete response), a disease control rate of 81% (26/32), and a progression-free survival of 9.3 months in all patients and 19.3 months in Xalkori (crizotinib)-naive patients with non-small cell lung cancer harboring a ROS1 rearrangement (PMID: 28520527; NCT01964157). 28520527
ROS1 rearrange non-small cell lung carcinoma sensitive Entrectinib Phase I Actionable In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in complete response in 2 and partial response in 10 patients with ROS-1 rearranged non-small cell lung carcinoma that were treatment-naive (PMID: 28183697). 28183697
ROS1 rearrange non-small cell lung carcinoma no benefit Alectinib Guideline Actionable Alecensa (alectinib) is not indicated for use in ROS1 rearranged non-small cell lung cancer patients whose disease became resistant to Xalkori (crizotinib) (NCCN.org). detail...
ROS1 rearrange lung adenocarcinoma sensitive Crizotinib Phase I Actionable In a retrospective analysis of Phase I clinical data, Xalkori (crizotinib) resulted in an objective response rate of 80% (24/30) and a median PFS of 9.1 months in patients with ROS1 rearranged lung adenocarcinoma (PMID: 25667280). 25667280
ROS1 rearrange non-small cell lung carcinoma sensitive Crizotinib Guideline Actionable Xalkori (crizotinib) is included in guidelines as the preferred first-line therapy for ROS1 rearranged non-small cell lung cancer (NCCN.org). detail...
ROS1 rearrange non-small cell lung carcinoma sensitive Crizotinib FDA approved Actionable In a Phase I trial that supported FDA approval, non-small cell lung cancer patients with ROS1 rearrangements treated with Xalkori (crizotinib) demonstrated an objective response rate of 72% (36/50), with 3 complete responses and 33 partial responses, a median duration of response of 17.6 months, and a median progression-free survival of 19.2 months (PMID: 25264305; NCT00585195). 25264305
ROS1 fusion KDR amp KIT amp PDGFRA amp non-small cell lung carcinoma predicted - resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of KIT, KDR, and PDGFRA (PMID: 29636358). 29636358
KIT D816G ROS1 fusion non-small cell lung carcinoma predicted - resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion developed resistance to treatment with Xalkori (crizotinib) and was subsequently found to have acquired KIT D816G (PMID: 29636358). 29636358
ROS1 fusion non-small cell lung carcinoma sensitive Lorlatinib Phase I Actionable In a Phase I clinical trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)). detail...
ROS1 fusion Advanced Solid Tumor predicted - sensitive Ropotrectinib Phase I Actionable In a Phase I (TRIDENT-1) trial, Ropotrectinib (TPX-0005) treatment resulted in partial response in 21.6% (8/37) of patients with advanced solid tumors harboring ROS1 or NTRK fusions (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116). detail...
ROS1 fusion Advanced Solid Tumor sensitive Brigatinib Preclinical - Cell culture Actionable In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 fusion proteins in culture (PMID: 27780853). 27780853
ROS1 fusion non-small cell lung carcinoma predicted - sensitive DS6051b Phase I Actionable In a Phase I clinical trial, DS-6051b was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res July 15 2016 (76) (14 Supplement) CT024). detail...
ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp non-small cell lung carcinoma predicted - resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358). 29636358
ROS1 fusion ERBB2 amp FGFR3 amp RET amp non-small cell lung carcinoma predicted - resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358). 29636358
ALK neg ROS1 pos non-small cell lung carcinoma sensitive Crizotinib Phase II Actionable In a Phase II trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022); NCT01945021). detail...
ROS1 positive pancreatic cancer predicted - sensitive Entrectinib Phase I Actionable In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in stable disease in a patient with ROS1-positive pancreatic cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)). detail...
ROS1 G2032R Advanced Solid Tumor predicted - sensitive Ropotrectinib Phase I Actionable In a Phase I (TRIDENT-1) trial, Ropotrectinib (TPX-0005) treatment resulted in partial response in a patient with advanced solid tumor harboring ROS1 G2032R in the context of ROS1 fusion (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116). detail...